RhumbLine Advisers
ZNTL icon

RhumbLine Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

RhumbLine Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Buy
+55,760
New +$223K ﹤0.01% 3135
2025
Q2 		– Sell
-84,542
Closed -$134K – 4276
2025
Q1 		$134K Sell
84,542
-7,672
-8% -$16.5K ﹤0.01% 3289
2024
Q4 		$279K Buy
92,214
+5,501
+6% +$18K ﹤0.01% 3032
2024
Q3 		$319K Sell
86,713
-7,500
-8% -$27.3K ﹤0.01% 2989
2024
Q2 		$385K Buy
94,213
+11,451
+14% +$128K ﹤0.01% 2845
2024
Q1 		$1.3M Buy
82,762
+1,962
+2% +$27K ﹤0.01% 2109
2023
Q4 		$1.22M Sell
80,800
-70
-0.1% -$1.02K ﹤0.01% 2149
2023
Q3 		$1.62M Buy
80,870
+14,070
+21% +$357K ﹤0.01% 1962
2023
Q2 		$1.88M Buy
66,800
+2,093
+3% +$50.2K ﹤0.01% 1939
2023
Q1 		$1.11M Buy
64,707
+6,730
+12% +$136K ﹤0.01% 2072
2022
Q4 		$1.17M Buy
57,977
+3,120
+6% +$67.1K ﹤0.01% 2048
2022
Q3 		$1.19M Buy
54,857
+9,173
+20% +$251K ﹤0.01% 2047
2022
Q2 		$1.28M Buy
45,684
+7,761
+20% +$206K ﹤0.01% 2016
2022
Q1 		$1.75M Buy
37,923
+2,475
+7% +$134K ﹤0.01% 1885
2021
Q4 		$2.98M Buy
35,448
+782
+2% +$60.5K ﹤0.01% 1666
2021
Q3 		$2.31M Buy
34,666
+2,776
+9% +$160K ﹤0.01% 1825
2021
Q2 		$1.7M Buy
31,890
+1,281
+4% +$68.6K ﹤0.01% 2021
2021
Q1 		$1.33M Sell
30,609
-1,848
-6% -$79.6K ﹤0.01% 2079
2020
Q4 		$1.69M Buy
32,457
+20,347
+168% +$918K ﹤0.01% 1926
2020
Q3 		$396K Sell
12,110
-1,031
-8% -$36.1K ﹤0.01% 2396
2020
Q2 		$631K Buy
+13,141
New +$504K ﹤0.01% 2242

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RhumbLine Advisers's ZNTL Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 55,760 shares worth $270K. The stake represents ﹤0.01% of the portfolio and ranks #3135 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ZNTL as recently as Q1 2025.

RhumbLine Advisers first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $2.98M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • RhumbLine Advisers held 55,760 shares of Zentalis Pharmaceuticals worth $270K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new RhumbLine Advisers position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3135 holding.
  • RhumbLine Advisers first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • RhumbLine Advisers's Zentalis Pharmaceuticals position peaked at $2.98M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.